OmniAb, Inc. (OABI) Earnings
OmniAb, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.11. OABI has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -1.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.10 | $-0.06 | +40.0% | $14M | +157.6% |
| Mar 4, 2026 | $-0.08 | $-0.11 | -37.5% | $8M | +48.3% |
| Nov 4, 2025 | $-0.14 | $-0.14 | -2.9% | $2M | -60.3% |
| Aug 6, 2025 | $-0.14 | $-0.15 | -7.1% | $4M | -31.0% |
| May 8, 2025 | $-0.17 | $-0.17 | +0.0% | $4M | -7.5% |
| Mar 18, 2025 | $-0.13 | $-0.12 | +7.7% | $11M | +65.3% |
| Aug 8, 2024 | $-0.18 | $-0.13 | +27.8% | $8M | +32.2% |
| May 9, 2024 | $-0.17 | $-0.19 | -11.8% | $4M | -35.2% |
| Mar 20, 2024 | $-0.17 | $-0.14 | +17.6% | $5M | -35.4% |
| Nov 9, 2023 | $-0.14 | $-0.16 | -14.3% | $5M | -47.0% |
| Aug 10, 2023 | $-0.11 | $-0.15 | -36.4% | $7M | -41.7% |
| May 11, 2023 | $0.05 | $-0.06 | -220.0% | $17M | -10.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
OmniApp had a strong start to 2026, largely driven by the advancement of partner programs. Technologies such as OmniUltra and OmniDAB are opening new markets and opportunities. The exploration platform, a proprietary, innovative, high - throughput single B - cell screening platform leveraging machine learning and AI, has strong interest. There were 107 active partners, 409 active programs, and 32 active clinical programs. Novel technology launches like OmniUltra were highlighted, and there were clinical advancements in partner programs. Upcoming clinical and regulatory events in 2026 were also mentioned, and partner programs to be featured at the ASCO conference were noted.
Guidance
The revenue outlook for 2026 has been revised to a range of 28 to 33 million. The GAAP operating expenses for 2026 are expected to be in the range of 83 to 88 million. The cash operating expense guidance remains unchanged at 50 to 55 million. The expected cash and cash equivalents at the end of 2026 are in the range of 33 to 38 million. The effective tax rate for the full year remains approximately 0% due to the valuation allowance.
Segment performance
Total revenue for the first quarter of 2026 was $14.4 million, compared to $4.2 million in the first quarter of 2025. The increase was mainly due to higher milestone revenue from the progress of partners' programs in the clinic. Operating expenses in the first quarter of 2026 were $22.3 million, a slight decrease from $23 million in the same period of 2025. Most of this decrease was from lower personnel and outside service costs. The net loss for the first quarter of 2026 was $7.7 million or six cents per share. The company ended the quarter with a cash position of $49.1 million. The updated 2026 revenue outlook is in the range of 28 to 33 million. GAAP operating expenses for 2026 are expected to be in the range of 83 to 88 million. Cash operating expense guidance remains at 50 to 55 million, and the expected cash and cash equivalents at the end of 2026 are in the range of 33 to 38 million.
Analyst Q&A
Q: As you mentioned, you have some ASCO data coming up for some of your partners. Are there milestones associated with these data releases, and are they in your current guidance, and more for your overall tech platforms. While you're constantly developing new ones, can you discuss any improvements and refinements to the existing that add to your marketability of those platforms?
A: Milestones are linked to clinical events. Regarding tech platforms, there are refinements and innovations in the chicken - based technologies and workflows, informed by deep partner relationships.
Q: One is around TEVA, the TEV408 with Phase 1B, the LIGO data expected in first half, and you were just talking about it, Matt. Milestone, when we think about milestones, would that be, would we have to wait until TEVA formally elects to move the program into Phase 2 or phase three, or at the end of phase one B, you know, knowing that they're moving ahead, is there a milestone there? And then second one is Immunovent, you know, recently announced Pitoclumab failed its phase three trials in TED. This was, at least for a section of investors, one of your most advanced and visible programs. Can you talk a little bit about how this impacts your long - term royalty projections in the context of having ImmunoVant, IMVT - 1402 as well?
A: Regarding TEVA, milestones are generally linked to clinical events. The ImmunoVant update had no impact on planning as they are focused on IMVT - 1402 which is advancing in multiple autoimmune diseases.
Q: We've been seeing a lot of pharma and academic users increasing their own adoption of AI within their workflows. So how should we think about how that rampant adoption should impact demand for your specific products and services? You know, do you expect the increase in partner model training could potentially accelerate demand for your platform, which is, you know, very data generating?
A: AI is seen as a tailwind. Omni is well - positioned as they have leveraged AI for a while and are excited about the impacts of AI across the industry.
Q: Know that you said you have this new license ad with Florida State and just kind of thinking about, I know you had said you share economics generated from partnerships like this, but I wanted to kind of dig a little deeper into kind of the differences in the economics associated with maybe a more academic deal versus a more industry focused deal and what kind of differences there are there and maybe if there's any kind of priority for one or the other moving forward.
A: Academic deals are structured for revenue share to enable asset monetization. There's no priority, but they are structured to attract partners.
Q: uh hey guys you have uh michael on here for beneath congrats on the quarter um my first question uh regards uh omni ultra i was wondering if you could offer any insights on um traction you're seeing with expanding into like new customer types or modalities that you highlighted peptides is one area that this model unlocks um any quality you can offer there And then I wanted to also ask on the new program start this quarter. It came in maybe a little bit softer than we were expecting, and we did have a larger tool company, particularly leverage of the preclinical space, highlight some headwinds in the early stage biotech affecting their results. I'm curious if you could offer any color on if you're seeing any of that or if this is just your standard fluctuations and starts.
A: OmniUltra has good reception with new customer types. Program starts are standard fluctuations due to lumpiness in program additions and timing of partner reports.
Q: Hey, guys, this is Kine on for Mike. Congratulations on the updates and thank you for taking our questions. Just a quick one on your active programs. You had nine additions and seven terminations and that, you know, based the guidance for this year. Just wanted to ask, is the value of the newer contracts higher than the older ones, or if you could provide some more color on that?
A: The average royalty rate has improved over time. Program additions and starts are linked to individual partners and contracts, with variety in their values.